一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300723 一品红

已收盘 06-12 15:00:00

{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":35.07,"timestamp":1781247801000,"preClose":34.12,"halted":0,"volume":10155187,"delay":0,"changeRate":0.0278,"floatShares":419000000,"shares":451999999,"eps":0.4428,"marketStatus":"已收盘","change":0.95,"latestTime":"06-12 15:00:00","open":34.02,"high":35.35,"low":33.5,"amount":351000000,"amplitude":0.0542,"askPrice":35.07,"askSize":59,"bidPrice":35.06,"bidSize":382,"shortable":0,"etf":0,"ttmEps":0.4428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.12,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":37.53,"lowLimit":30.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":7.96,"roa":"--","peRate":79.200542,"roe":"35.91%","epsLYR":-0.7478,"committee":-0.51398,"marketValue":15841000000,"turnoverRate":0.0242,"status":0,"floatMarketCap":14701000000},"requestUrl":"/m/hq/s/300723/","defaultTab":"news","newsList":[{"id":"2642446677","title":"一品红(300723.SZ)子公司创新药APH03571片获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446677","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642446677?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:53","pubTimestamp":1781078020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请已获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开展临床试验。APH03571是公司研制的拟用于携带FLT3(全称：FMS-like tyrosine kinase 3)突变的复发性或难治性急性髓系白血病成人患者的治疗药品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","300723","06978","BK0239","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414727","title":"一品红：AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414727?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:30","pubTimestamp":1781062222,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，AR882Ⅲ期目前处于数据锁库还是随访收尾阶段？EULAR大会是否会披露阶段性临床数据？2025年11月，公司在研的痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组。目前，正在进行关键性Ⅲ期临床试验，试验进展顺利。公司将严格按照相关法律法规要求履行信息披露义务。敬请广大投资者谨慎决策，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000016990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182158","title":"一品红(300723.SZ)子公司创新药APH04935片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182158","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640182158?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:12","pubTimestamp":1780560741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH04935片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH04935片是由公司自主研发的一种高活性、高选择性的小分子GLP-1R激动剂，目标成为一款一天给药一次的口服小分子GLP-1R激动剂，拟用于成人超重或肥胖患者的体重减轻及长期减重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","159992","BK1574","300723","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640720919","title":"一品红(300723)5月31日股东户数3.6万户，较上期减少14.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640720919","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640720919?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:37","pubTimestamp":1780393041,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年5月31日公司股东户数为3.6万户，较4月30日减少5967.0户，减幅为14.21%。在化学制药行业个股中，一品红股东户数高于行业平均水平，截至5月31日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年4月30日至2026年5月31日，一品红区间涨幅为5.93%，在此期间股东户数减少5967.0户，减幅为14.21%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913423","title":"一品红：截止至2026年5月31日，公司股东总户数36,010户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640913423?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:57","pubTimestamp":1780387031,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：现在股东人数一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2026年5月31日，公司股东总户数36,010户。祝您投资愉快。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200026929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640965798","title":"股市必读：一品红（300723）6月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640965798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640965798?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:01","pubTimestamp":1780333277,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，一品红报收于42.4元，下跌3.44%，换手率4.41%，成交量18.49万手，成交额7.94亿元。董秘最新回复投资者： 目前疼风药成功上市，会是治疗疼风石的唯一药品吗？目前，公司股东已收到SOBI公司的投资并购首付款，正在履行必要的程序，公司控股股东将会尽快履行承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640543639","title":"一品红：控股股东承诺无偿给予Arthrosi股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640543639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640543639?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:48","pubTimestamp":1780318097,"startTime":"0","endTime":"0","summary":"公司控股股东广润集团承诺待上述交易完成后，将其子公司 Guangrun Health 持有Arthrosi 的 9.07%股权按照 E 轮投资后的净收益无偿、无条件给予公司，支持公司研发创新发展。目前，公司股东已收到SOBI公司的投资并购首付款，正在履行必要的程序，公司控股股东将会尽快履行承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100037905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669431","title":"5月28日一品红发生1笔大宗交易 成交金额1410.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638669431?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:27","pubTimestamp":1779960421,"startTime":"0","endTime":"0","summary":"证券之星消息，5月28日一品红发生大宗交易，交易数据如下：大宗交易成交价格40.3元，相对当日收盘价折价0.81%，成交35万股，成交金额1410.5万元，买方营业部为国泰海通证券股份有限公司上海自贸试验区第二分公司，卖方营业部为中国中金财富证券有限公司上海黄浦区中山东二路证券营业部。近三个月该股共发生1笔大宗交易，合计成交3500.0手，折价成交1笔。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387542","title":"一品红最新公告：全资子公司获氨基己酸注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637387542?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:40","pubTimestamp":1779360004,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，全资子公司广州一品红制药近日收到国家药监局核准签发的氨基己酸注射液《药品注册证书》，该药品为化学药品3类，视同通过一致性评价，用于预防及治疗血纤维蛋白溶解亢进引起的各种出血。2025年该药品在中国城市和县级公立医院销售规模约7388万元。此次获批将进一步丰富公司产品管线，增强核心竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637243048","title":"股市必读：一品红（300723）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637243048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637243048?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:12","pubTimestamp":1779297131,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，一品红报收于38.18元，下跌0.78%，换手率2.27%，成交量9.51万手，成交额3.63亿元。董秘最新回复投资者： 公司是否已经开始组建 AR882 的商业化团队？2025年8月，公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组；2025年11月，AR882国内Ⅲ期临床试验完成全部患者入组。公司将严格按照相关法律法规要求履行信息披露义务。当日关注点来自交易信息汇总：5月20日主力资金净流出3558.94万元，散户资金净流入3737.08万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100001746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817159","title":"一品红：氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636817159?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267637,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问AR882氘泊替诺雷国内三期临床是否按计划6月完成收尾？2025年8月，公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组；2025年11月，AR882国内Ⅲ期临床试验完成全部患者入组。目前，AR882正在进行关键性Ⅲ期临床试验，相关试验开展顺利，产品上市时间可期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636175108","title":"一品红：公司正在有序规划及准备AR882后续上市后的商业化事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2636175108","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636175108?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:57","pubTimestamp":1779267434,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否已经开始组建 AR882 的商业化团队？团队规模和人员构成是怎样的？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司正在有序规划及准备AR882后续上市后的商业化事宜，公司会制定切实可行的完整的商业化市场方案，在产品上市前逐步调整到位。药品研发具有周期长、投入高、风险大等特点，敬请广大投资者谨慎决策，注意投资风险。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814889","title":"一品红：AR882正在进行关键性Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814889?lang=zh_cn&edition=full","pubTime":"2026-05-20 15:57","pubTimestamp":1779263825,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，AR882的R2预计在q2发布，近期公司股价持续走低，请问公司数据是否存在泄露情况，如信立泰一样，结果不及预期一品红回复：尊敬的投资者您好，感谢您对公司的关注。股价波动受资本市场环境、公司经营等多种综合因素的影响。目前，AR882正在进行关键性Ⅲ期临床试验，试验进展顺利。公司将严格按照相关法律法规要求履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000026316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636859150","title":"一品红：2024年8月AR882被美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2636859150","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636859150?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:52","pubTimestamp":1779195159,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红05月19日在投资者关系平台上答复投资者关心的问题。请问这对其在美国的上市进程有何帮助？2024年 8 月 AR882 被美国 FDA 授予快速通道资格认定。这一认定适用于AR882在治疗临床痛风患者可见痛风石方面的应用，是AR882研发历程中的重要里程碑，将有助于加速推进该药的临床试验和注册上市进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900041284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833871","title":"一品红：坚持以儿童临床需求为导向","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833871?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175103,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：儿童药的研发难度大、周期长，公司如何保持在儿童药领域的研发优势？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司坚持以儿童临床需求为导向，采取自主研发与合作开发等模式相结合，致力于儿童用药的全面技术创新，以提高儿童专用制剂的研发水平，研制口感佳、安全性高、剂量精准的儿童药物，重点解决儿童用药依从性差、安全隐患多等临床难题。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833847","title":"一品红：降尿酸及痛风药市场未来十分可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833847?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175102,"startTime":"0","endTime":"0","summary":"据《中国高尿酸血症与痛风诊疗指南》，中国高尿酸血症的总体患病率为13.3%，痛风总体发病率为1.1%。根据弗若斯特沙利文预测，中国高尿酸血症患者人数从2019年的1.83亿人增至2024年的2.21亿人，年复合年增长率为3.8%，且预计到2033年将达2.86亿人，2024年至2033年的年复合增长率2.9%。降尿酸及痛风药市场未来十分可期。此外，药品获批上市后的生产和销售将受到市场、环境变化等不确定因素影响，存在销售不达预期的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636338468","title":"一品红：相关政策的出台为行业企业的发展带来了积极影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2636338468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636338468?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:18","pubTimestamp":1779175102,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：国家出台了多项支持儿童药发展的政策，请问这些政策对公司的儿童药业务有何积极影响？一品红回复：尊敬的投资者您好，感谢您对公司的关注。国家相关部门始终高度重视儿童药品的发展。涵盖儿童用药保障需求、鼓励研发、优先审评、简化采购程序、扩大医保支付范围等多个方面。相关政策的出台为行业企业的发展带来了积极影响。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833843","title":"一品红：AR882正在进行关键性Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833843?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:15","pubTimestamp":1779174919,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：AR882 的成功研发对公司从传统仿制药企向创新药企转型具有怎样的里程碑意义？一品红回复：尊敬的投资者您好，感谢您对公司的关注。目前，AR882正在进行关键性Ⅲ期临床试验，尚处于临床研究阶段。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071100","title":"一品红（300723）披露2025年度股东会法律意见书，5月18日股价下跌3.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071100?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:04","pubTimestamp":1779113096,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，一品红报收于38.75元，较前一交易日下跌3.34%，最新总市值为175.03亿元。近日，一品红药业集团股份有限公司披露北京市中伦（广州）律师事务所出具的《关于一品红药业集团股份有限公司2025年度股东会的法律意见书》。法律意见书指出，本次股东会的召集、召开程序、出席人员资格、表决程序及表决结果均符合相关法律法规及公司章程规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800036955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634268476","title":"一品红：公司在研的创新药氘泊替诺雷（AR882）是一种高效选择性尿酸转运蛋白（URAT1）抑制剂，用于降低血尿酸治疗痛风及溶解痛风石","url":"https://stock-news.laohu8.com/highlight/detail?id=2634268476","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634268476?lang=zh_cn&edition=full","pubTime":"2026-05-12 11:33","pubTimestamp":1778556808,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月11日在投资者关系平台上答复投资者关心的问题。投资者提问：5月15日,ASCO会摘录贵公司疼风药第三期临床结果吗一品红回复：尊敬的投资者您好，感谢您对公司的关注。ASCO是临床肿瘤学领域的学术会议。公司在研的创新药氘泊替诺雷（AR882）是一种高效选择性尿酸转运蛋白（URAT1）抑制剂，用于降低血尿酸治疗痛风及溶解痛风石。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200016638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK1574","300723","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781460333614,"stockEarnings":[{"period":"1week","weight":-0.0668},{"period":"1month","weight":-0.1513},{"period":"3month","weight":0.0874},{"period":"6month","weight":-0.2482},{"period":"1year","weight":-0.4056},{"period":"ytd","weight":0.0453}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36010人(较上一季度减少14.21%)","perCapita":"11640股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":"　　一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系，结合多年的市场经验，公司形成了覆盖面广、重点突出、阶梯化储备的产品结构，聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日，公司（含全资及控股子公司）新增技术发明专利5项，目前，公司共有专利125项，其中国内专利114项，境外专利11项；共有商标477项，软件著作权45项。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}